• Markets
    • icon
  • Companies
AGN · ASX

Argenica Therapeutics Ltd (ASX:AGN)

AU$0.81

 -0.01 (-1.22%)
ASX:Live
16/09/2024 03:54:25 PM
Hammer Bearish HALO Ords GROWTH AUS Consensus Cheap All-Consensus +1
Consensus Score
/10
Recommend
Lock
Target Price
Lock
Deviation
Lock
Unlock Full Consensus Insights

AGN Overview

AGN Health Scores

Short Term

Mean Reversion

Neutral

Trend

Neutral

Event

Neutral

Halo Model

MQV

Very Strong

GARP

Very Strong

MQV Small

Neutral

Valuation

Value

Consensus

Momentum

Price

Weak

Earnings

Very Strong

Growth

Earnings

Very Strong

Dividends

Very Strong

Quality

Capital Efficiency

Very Strong

Balance Sheet

Very Strong

About AGN

Website

N/A

Telephone

61.8.9329.3396

Address

Unit 4, 117 Broadway Nedlands, Western Australia (WA) 6009

Description

Argenica Therapeutics Ltd. provides neuroprotective treatment. It specializes in development and commercialization of a novel therapeutic known as ARG-007. It offers drug ARG-007 in multiple models of stroke and other central nervous system (CNS) injury models, specifically: stroke including non-human primates; traumatic brain injury; and perinatal hypoxia ischaemia. The company was founded on 20 November 2019 and is headquartered in Nedlands, Australia.

AGN Price Chart

Key Stats

Market Cap

AU$104.25M

PE

13.90

EV/EBITDA

0.0

Dividends Overview

DIV Yield

1.0%

Franking

N/A

Ex Dividend Date (est.)

N/A

Market Data

52 weeks range

Low 0.29 - 0.99

Trade Value (12mth)

AU$27,601.00

1 week

4.46%

1 month

-1.2%

YTD

56.19%

1 year

112.99%

All time high

1.02

Key Fundamentals

EPS 3 yr Growth

274.50%

EBITDA Margin

N/A

Operating Cashflow

-$5m

Free Cash Flow Return

-46.80%

ROIC

-50.70%

Interest Coverage

N/A

Quick Ratio

6.70

Other Data

Shares on Issue (Fully Dilluted)

105m

HALO Sector

Healthcare

Next Company Report Date

20-Aug-25

Ex Dividend Date (est.)

N/A

Next Dividend Pay Date (est.)

N/A

Reporting Currency

AUD

Short Sell (% of issue)

0.00

AGN Announcements

Latest Announcements

Date Announcements

06 September 24

Positive DSMB Safety Outcome & Phase 2 Trial Progress Update

×

Positive DSMB Safety Outcome & Phase 2 Trial Progress Update

28 August 24

Appendix 4E & Annual Report to 30 June 2024

×

Appendix 4E & Annual Report to 30 June 2024

28 August 24

Appendix 4G & Corporate Governance Statement

×

Appendix 4G & Corporate Governance Statement

14 August 24

Results of Meeting

×

Results of Meeting

14 August 24

Notification regarding unquoted securities - AGN

×

Notification regarding unquoted securities - AGN

14 August 24

Change of Director's Interest Notice

×

Change of Director's Interest Notice

08 August 24

Application for quotation of securities - AGN

×

Application for quotation of securities - AGN

08 August 24

Notification of cessation of securities - AGN

×

Notification of cessation of securities - AGN

08 August 24

Cleansing Notice

×

Cleansing Notice

08 August 24

Change of Director's Interest Notice x3

×

Change of Director's Interest Notice x3

31 July 24

Quarterly Activities/Appendix 4C Cash Flow Report

×

Quarterly Activities/Appendix 4C Cash Flow Report

24 July 24

Phase 2 Stroke Clinical Trial Update

×

Phase 2 Stroke Clinical Trial Update

22 July 24

Investor Webinar Presentation

×

Investor Webinar Presentation

15 July 24

Investor Presentation

×

Investor Presentation

12 July 24

Notice of General Meeting/Proxy Form

×

Notice of General Meeting/Proxy Form

09 July 24

Notice of initial substantial holder from IFL

×

Notice of initial substantial holder from IFL

14 June 24

Application for quotation of securities - AGN

×

Application for quotation of securities - AGN

14 June 24

Notification of cessation of securities - AGN

×

Notification of cessation of securities - AGN

14 June 24

Cleansing Notice

×

Cleansing Notice

12 June 24

Notification of cessation of securities - AGN

×

Notification of cessation of securities - AGN

05 June 24

Application for quotation of securities - AGN

×

Application for quotation of securities - AGN

05 June 24

Notification of cessation of securities - AGN

×

Notification of cessation of securities - AGN

05 June 24

Cleansing Notice

×

Cleansing Notice

05 June 24

Change of Director's Interest Notice

×

Change of Director's Interest Notice

05 June 24

Non-Executive Director Resignation

×

Non-Executive Director Resignation

AGN Fundamentals

Per Share Records

Historical data

Forecast data

AUD 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027
Per Share, Growth & Valuations
EPS (Basic) $ Lock Lock Lock Lock -0.06 -0.06 -0.05 Lock Lock Lock
EPS (Fully Diluted) $ Lock Lock Lock Lock -0.06 -0.06 -0.05 Lock Lock Lock
     Growth % Lock Lock Lock Lock -292.2 0.5 4.0 Lock Lock Lock
     PE X Lock Lock Lock Lock N/A 9.3 13.9 Lock Lock Lock
     EV/EBITDA X Lock Lock Lock Lock N/A 1.0 0.0 Lock Lock Lock
CFPS $ Lock Lock Lock Lock -0.04 -0.04 -0.04 Lock Lock Lock
FCFPS $ Lock Lock Lock Lock -0.05 -0.04 0.00 Lock Lock Lock
     Growth % Lock Lock Lock Lock -305.3 -5.0 2.5 Lock Lock Lock
     Yield % Lock Lock Lock Lock -10.6 -10.0 0.0 Lock Lock Lock
DPS $ Lock Lock Lock Lock 0.00 0.00 0.00 Lock Lock Lock
     Growth % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
     Yield % Lock Lock Lock Lock N/A 1.6 1.0 Lock Lock Lock
     Payout Ratio % Lock Lock Lock Lock 0 0 0 Lock Lock Lock
BPS $ Lock Lock Lock Lock 0.10 0.08 0.11 Lock Lock Lock
BPS (Tangible) $ Lock Lock Lock Lock 0.10 0.08 0.11 Lock Lock Lock
     Growth % Lock Lock Lock Lock 2.1 -18.4 44.7 Lock Lock Lock
Shares Outstanding
Diluted m Lock Lock Lock Lock 74 88 104 Lock Lock Lock
Basic m Lock Lock Lock Lock 74 88 104 Lock Lock Lock

Financial Records

Historical data

Forecast data

AUD 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027
Income Statement
Sales $m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
     Growth % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
Selling & General Expenses $m Lock Lock Lock Lock 4 7 8 Lock Lock Lock
Gross Income $m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
     Growth % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
     Margin % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
Cost of Goods Sold to Sales % Lock Lock Lock Lock 0 0 0 Lock Lock Lock
EBITDA $m Lock Lock Lock Lock -4 -7 -8 Lock Lock Lock
     Growth % Lock Lock Lock Lock -228.2 -52.2 -24.8 Lock Lock Lock
     Margin % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
Depreciation & Amortisation $m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
EBIT $m Lock Lock Lock Lock -4 -7 -8 Lock Lock Lock
     Growth % Lock Lock Lock Lock -228.2 -52.2 -24.8 Lock Lock Lock
     Margin % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
Pretax Income $m Lock Lock Lock Lock -4 -6 -8 Lock Lock Lock
Income Taxes $m Lock Lock Lock Lock 0 -1 -2 Lock Lock Lock
Net Income $m Lock Lock Lock Lock -4 -5 -5 Lock Lock Lock
     Growth % Lock Lock Lock Lock -297.4 -17.7 -13.8 Lock Lock Lock
     Margin % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
Cash Flow Statement
Net Operating Cash Flow $m Lock Lock Lock Lock -3 -3 -5 Lock Lock Lock
Capital Expenditures $m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
Net Investing Cash Flow $m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
Net Financing Cash Flow $m Lock Lock Lock Lock 5 4 12 Lock Lock Lock
Free Cash Flow $m Lock Lock Lock Lock -3 -3 0 Lock Lock Lock
     Growth % Lock Lock Lock Lock -221.3 1.8 100.0 Lock Lock Lock
     Margin % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
Franking Balance $m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
Balance Sheet
Cash & Short-Term Investments $m Lock Lock Lock Lock 9 9 16 Lock Lock Lock
Total Assets $m Lock Lock Lock Lock 9 10 16 Lock Lock Lock
Long Term Debt $m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
Net Debt $m Lock Lock Lock Lock -9 -9 -16 Lock Lock Lock
Total Liabilities $m Lock Lock Lock Lock 1 2 2 Lock Lock Lock
Equity $m Lock Lock Lock Lock 8 8 14 Lock Lock Lock
Invested Capital Lock Lock Lock Lock 8 8 14 Lock Lock Lock
     Growth % Lock Lock Lock Lock 21.3 -7.7 82.0 Lock Lock Lock
Return Ratios
Return on Assets % Lock Lock Lock Lock -45.2 -50.5 -33.5 Lock Lock Lock
Return on Equity % Lock Lock Lock Lock -49.2 -62.8 -39.3 Lock Lock Lock
Return on Total Capital % Lock Lock Lock Lock -57.4 -82.9 -76.5 Lock Lock Lock
Return on Invested Capital % Lock Lock Lock Lock -54.0 -60.3 -50.7 Lock Lock Lock
Cash Flow Return on Invested Capital % Lock Lock Lock Lock -44.4 -41.3 -46.8 Lock Lock Lock

Ratios Records

Historical data

Forecast data

AUD 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027
Leverage
Interest Cover X Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
Debt to EBITDA X Lock Lock Lock Lock 2.0 1.4 1.9 Lock Lock Lock
Net Debt to Equity % Lock Lock Lock Lock -107.3 -121.8 -114.1 Lock Lock Lock
Liquidity
Current Ratio X Lock Lock Lock Lock 12.3 5.1 6.7 Lock Lock Lock
Quick Ratio X Lock Lock Lock Lock 12.3 5.1 6.7 Lock Lock Lock
Cash & ST Inv/Current Assets % Lock Lock Lock Lock 98.6 97.9 97.2 Lock Lock Lock
CFO/Current Liabilities % Lock Lock Lock Lock -456.8 -176.1 -208.5 Lock Lock Lock
Balance Sheet Efficiency
Receivables Turnover X Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
Inventory Turnover X Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
Working Capital Turnover X Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
Payables Turnover X Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
Asset Turnover X Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
Du Pont
Asset Turnover X Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
x Pretax Margin % Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
= Pretax Return on Assets % Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
x Tax Rate Complement (1-Tax Rate) % Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
Return on Assets % Lock Lock Lock Lock -45.2 -50.5 -33.5 Lock Lock Lock
x Equity Multiplier (Assets/Equity) % Lock Lock Lock Lock 1.1 1.2 1.2 Lock Lock Lock
Return on Equity % Lock Lock Lock Lock -49.2 -62.8 -39.3 Lock Lock Lock
x Earnings Retention (1-Payout) % Lock Lock Lock Lock 100.0 100.0 100.0 Lock Lock Lock
= Reinvestment Rate (%) % Lock Lock Lock Lock -49.2 -62.8 -39.3 Lock Lock Lock
Operating Cycle
Days of Inventory on Hand Days Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
+ Days of Sales Outstanding Days Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
Operating Cycle Days Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
- Days of Payables Outstanding Days Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
Net Operating Cycle Days Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock

Dividends

Key Stats

Ex Dividend Date (est.)

N/A

DIV Yield

1.0%

Franking Level

N/A

DPSg

N/A

Quality Yield

Lock

Falling Divs over next 2

Lock

Values and Recommendations

Key Stats

Consensus Score

Lock

Recommendation

Lock

EPS 1 month Change

Lock

Quality Yield

Lock

Falling Divs over next 2

Lock

Halo Consensus Score

Lock Chart

PEG Ratio

Lock Chart

Consensus EPS Revisions

Lock Chart

Short selling

Key Stats

Percent of Issue

0.00%

Value ($M)

0

Prior Change

N/A

7 Day Change

N/A

1 Month Change

N/A

3 Month Change

N/A

Discover
Short-selling
Opportunities

Access data on short interest, stock performance, and potential short-selling candidates across various markets to make informed decisions and optimize your trading strategies.

AGN Shortsell

Frequently Asked Questions

The current share price of Argenica Therapeutics Ltd (AGN:ASX) is AU$0.81.
The 52-week high share price for Argenica Therapeutics Ltd (AGN:ASX) is AU$0.99.
The 52-week low share price for Argenica Therapeutics Ltd (AGN:ASX)? is AU$0.29.
The current TTM dividend payout for Argenica Therapeutics Ltd (AGN:ASX) is 1.00.
Argenica Therapeutics Ltd (AGN:ASX) does not pay a dividend.
Argenica Therapeutics Ltd (AGN:ASX) has a franking level of 0.0%.
Argenica Therapeutics Ltd (AGN:ASX) is classified in the Healthcare.
The current P/E ratio for Argenica Therapeutics Ltd (AGN:ASX) is 13.90.
logo
Login
Company
Company
Important

Get the latest insights and hot tips delivered right to your inbox

App Store Google Play

HALO Technologies Pty Ltd ABN 54 623 830 866 is a Corporate Authorised Representative No 1261916 of Macrovue Pty Ltd ABN 98 600 022 679 AFSL 484264. Macrovue Pty Ltd is a wholly owned subsidiary of HALO Technologies Pty Ltd.